ArticleGenome biology2026
FIRST-seq: a nanopore-based cDNA sequencing platform for RNA modification and structure profiling.
Article in Genome biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FIRST-seq: a nanopore-based cDNA sequencing platform for RNA modification and structure profiling.Genome biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA modifications induce reverse transcription (RT) errors in an enzyme- and context-dependent manner, enabling transcriptome-wide mapping and RNA structure probing. We present FIRST-seq, a flexible, cost-effective nanopore cDNA method that avoids second-strand synthesis and PCR, making it compatible with any RT enzyme and enabling single-nucleotide resolution RT signature analysis. Benchmarking multiple RT enzymes and buffers identified conditions that reduce premature termination and enhance error detection. Coupled with DMS probing, FIRST-seq accurately detects m1A and m3C at unpaired sites, recapitulating known RNA structures in vitro and in vivo. FIRST-seq offers a versatile platform for profiling chemical-induced and natural RNA modifications using long-read sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.